Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 3Terminated 2Recruiting 2Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Leukemia, Myeloid, Acute 17Myelodysplastic Syndromes 8Recurrence 2Leukemia, Myelomonocytic, Chronic 2Triple Negative Breast Neoplasms 1Spinocerebellar Degenerations 1Sarcoma 1Pathologic Complete Response 1Ovarian Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Neoplasm, Residual 1Melanoma 1Medulloblastoma 1Lymphoma 1Leukemia 1Graft vs Host Disease 1Ependymoma 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

Paclitaxel 28Trastuzumab 22Cyclophosphamide 21Doxorubicin 14Docetaxel 14Carboplatin 11exemestane 10Radiotherapy 10Letrozole 10Capecitabine 10pembrolizumab 8Lapatinib 8Fulvestrant 8Neoadjuvant Therapy 6Goserelin 6Bevacizumab 6Anastrozole 6pertuzumab 5palbociclib 5eribulin 5abemaciclib 5Therapeutics 5Magnetic Resonance Spectroscopy 5Epirubicin 5Chemotherapy, Adjuvant 5Aromatase Inhibitors 5tucatinib 4Vinorelbine 4Taxes 4Tamoxifen 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Breast Neoplasms × Azacitidine × Clear all
NCT01292083 2014-02-06

Azacitidine in Treating Patients With Triple Negative Stage I-IV Invasive Breast Cancer That Can Be Removed By Surgery

University of Southern California

Phase NA Withdrawn
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡